Condition
ALI
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Withdrawn2
Unknown1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT04360096Phase 2Terminated
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19
NCT05137795Phase 3Withdrawn
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
NCT04503057Unknown
Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
NCT04574869Phase 1Withdrawn
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
Showing all 4 trials